Effect of Early Administration of TXA in Adult Hip Fractures

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorAscension Health

About this trial

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.

Eligibility criteria

Qualifiers

1. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation

Disqualifiers

Polytrauma patients

Previous operation on the ipsilateral hip

Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)

Patients with < 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)

Trial design

Treatments tested in this trial

  • Tranexamic acid

Treatment groups

170 Participants
are divided into 2 treatment groups

Sponsors and collaborators